Reliance Life Sciences is a medical biotechnology-led company engaged in research and development, manufacturing and marketing of differentiated medical products and services, used to treat patients primarily in intensive and critical care units in hospitals. Three core businesses of RLS are plasma proteins, biosimilars, and later generation oncology pharmaceuticals. In addition, it has initiatives in clinical research, molecular medicine, regenerative medicine, genetherapy, peptides and oligonucleotides.

Jodas is a Global, specialty, innovation driven, emerging, generic bio- pharmaceutical company, that is asserting itself among the worlds foremost pharmaceutical companies. JEPL is having EU GMP certification of Oncology (orals), Contrast Media (SVP and LVP) and facility for Cephalosporins currently delivering the products like Anti-Cancer and Antibiotics.

Applying Candidate Should Be Open to Travel & Work Overseas.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.

Post : Research Associate in Formulation and Drug Product Development group

AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season. Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season.

For decades, it has been known that people with diabetes are at a substantially increased risk of developing severe lung disease if they become infected with viruses such as influenza, as well as with bacteria and fungi. When the COVID-19 pandemic started in early 2020, this mysterious phenomenon gained even more pressing importance: It became clear that people with diabetes were at a significantly higher risk of coming down with severe, even fatal, lung disease after developing a serious form of the virus, but no one understood why.

Staff Selection Commission(J.S.S.C.) has been constituted by the state Staff Selection Commission Act 2008which was published vide Gazette notification no. 829 dt. 6 December 2008 of state Government. The Act was amended by Jharkhand Act 03,2011 and Jharkhand Act 19,2011; published vide Gazette notification nos. 153 dt. 24 February 2011 and 687 dt. 11 October 2011 respectively.

Post : Pharmacist

Indian Council of Medical Research (ICMR) is an Autonomous Organization, under the Department of Health Research, Ministry of Health 6 Family Welfare, Govt, of India. ICMR is dealing with biomedical/ health research in various areas, in collaboration with national/ international agencies, through its Headquarters at New Delhi and 27 Institutes / Centres and a large number of field stations, situated across the country.

The Chief Executive Officer (CEO) of Dr.YSR Aarogya Sri Health Care Trust, Govt. of A.P., Mangalagiri has accorded permission to fill up all the vacant posts of Aarogya Mithras and Team Leaders on outsourcing basis at Dr.YSR Net Work Hospitals in Prakasam District on consolidated pay through District Selection Committee under the chairmanship of Collector and District Magistrate, Prakasam District, Ongole to provide better medical facilities to the BPL families.

Post : Aarogya Mithras, Team Leaders

National AYUSH Mission is a Centrally Sponsored Scheme under the Ministry of AYUSH. The government of India launched National AYUSH Mission (NAM) during the 12th plan in 2014. In Kerala, NAM started activities in 2015. The aim of NAM is to mainstream AYUSH Systems into health care services, to develop evidence-based AYUSH management protocol through scientific documentation and to ensure the accessibility of quality AYUSH services. Regarding the funding pattern, 60% share is provided by the Central Government and 40% is provided by the State Government.

CSMCRI with much scientific excitement has now achieved technological excellence with several granted patents in the core mandate of the institute and is one among the top performing national R&D laboratories in the country. At the beginning of 2011, the Institute has around 360 staff with 150 S&T staff on its roll and around 250 research fellows and project assistants pursing their doctoral programme.

Post : Junior Research Fellow (JRF) under CSIR GATE scheme

The Birla Institute of Technology & Science, BITS Pilani, is an all-India Institute for higher education. The primary aim of BITS is to "train young men and women able and eager to create and put into action such ideas, methods, techniques, and information. The Institute is a dream come true of its founder, the late Mr G.D. Birla, an eminent industrialist, a participant in the Indian freedom struggle, and a close associate of Mahatma Gandhi.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. Today, Intas is present in more than 85 countries worldwide and is growing at 20% CAGR. Around 70% of its revenues come from the international markets, particularly the highly regulated markets of EU and US. At Intas, every day and everyone works to create a world of good health, happiness and hope.

Walk In Drive for Quality Control

Medreich is a fully integrated pharmaceutical company with an established presence across the globe. The company is involved in the CMO & CDMO business of pharmaceutical preparations in various dosage forms catering to diverse Therapeutic categories.  Medreich has an advanced state of the art Research and Development centre with proven scientific competence to develop formulations as Patent Non-infringing and Niche generics in differentiated dosage form for global regulated markets.

Hetero Drugs is an Indian pharmaceutical company and the world’s largest producer of anti-retroviral drugs. Hetero’s business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics. Globally renowned, vertically integrated pharmaceutical player engaged in Research and Development (R&D), manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas.

Opening’s in Regulatory Affairs

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. Today, Intas is present in more than 85 countries worldwide and is growing at 20% CAGR. Around 70% of its revenues come from the international markets, particularly the highly regulated markets of EU and US. At Intas, every day and everyone works to create a world of good health, happiness and hope.

Walk In Drive at Matoda

Vayam Research Solutions, a privately owned company & a young, vibrant organization with experienced pharma professionals is a dynamic, adept- based clinical research organization based out of Ahmedabad (Gujarat), India. Vayam research solutions (A Clinical Research Organization) is an offering from Sarvotham group.

Principal Investigator (PI)
Qualifications : MD (Pharmacology) / MBBS
Experience : 4 -5 years of experience in CRO

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries

Doctors from Tata Memorial Hospital, Mumbai, and the Advanced Centre for Training Research and Education in Cancer (ACTREC), Navi Mumbai, collaborated with IDRS Labs, Bangalore, to develop the first and only oral suspension of 6-mercaptopurine (6-MP) in India. 6-MP is a chemotherapy drug used in the treatment of Acute Lymphoblastic Leukemia (ALL), the most common type of blood cancer afflicting children. The child friendly formulation is available in the form of a Powder for Oral Suspension, and is marketed under the tradename PREVALL.

Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.